Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o
β¦ LIBER β¦
What to do with the long-stay psychiatric patient? A review of a hundred cases
β Scribed by E. Fottrell; J. L. Majumder
- Publisher
- Springer-Verlag
- Year
- 1975
- Tongue
- English
- Weight
- 431 KB
- Volume
- 10
- Category
- Article
- ISSN
- 1433-9285
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Is it possible to discontinue imatinib m
β
Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria
π
Article
π
2009
π
Elsevier Science
π
English
β 111 KB
Complete hematologic and cytogenetic res
β
Alvaro Aguayo; Jorge E. Cortes; Hagop M. Kantarjian; Miloslav Beran; Varsha Gand
π
Article
π
1999
π
John Wiley and Sons
π
English
β 97 KB
π 1 views
## BACKGROUND. T-cell lymphoid blastic phase (BP) transformation is rare in chronic myelogenous leukemia (CML). 2-amino-9-β€-D-arabinosyl-6-methoxy-9H-guanine (GW506U78), a prodrug of arabinosylguanine (ara-G), is effective in T-cell leukemias. ## METHODS. The authors present a case of a 48-year
Renal insufficiency and anemia are indep
β
Langston, Robert D.; Presley, Rodney; Flanders, W. Dana; Mcclellan, William M.
π
Article
π
2003
π
Nature Publishing Group
π
English
β 373 KB